Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 472-477

  Cromwell, Ian ^a   van der Hoek, Kimberly ^a   Malfair Taylor, Suzanne C ^b   Melosky, Barbara ^c   Peacock, Stuart ^a,d  

^a Canadian Centre for Applied Research in Cancer Control ARCC   (Canada)

^b MINISTRY OF HEALTH   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cost effectiveness; Erlotinib; Health economics; Real world; Retrospective study

Indexed keywords

ERLOTINIB; LIVER ENZYME;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANADA; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION TO DEATH SURVIVAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860542210     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.003     Document Type: Article

References (11)

1. Committee, C.C.S.s.S. Canadian Cancer Statistics 2009. 2010 [cited 2009 April 9th, 2010]; Available from: http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/~/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/pdf%20not%20in%20publications%20section/Stats%202009E%20Cdn%20Cancer.ashx.
2. Neville A. Lung cancer. Clinical Evidence 2008, 4:1-31.
3. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously-treated non-small-cell lung cancer. The New England Journal of Medicine 2005, 353(2):123-132.
4. Bezjak A., Tu D., Seymour L., Clark G., Trajkovic A., Zukin M., et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology 2006, 24(24):3831-3837.
5. Agency BC. BCCA Protocol Summary for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib. 2009 [cited 2010; Available from: http://www.bccancer.bc.ca/NR/rdonlyres/5743F797-D252-42DB-B689-339C079C904B/38143/LUAVERL_Protocol_1Aug09.pdf.
6. Jack B., Boland A., Dickson R., Stevenson J., McLeod C. Best supportive care in lung cancer trials in inadequately described: a systematic review. European Journal of Cancer Care 2009, E-publication ahead of print: p. 1-9.
7. Bradbury P.A., Tu D., Seymour L., Isogai P.K., Zhu L., Ng R., et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. Journal of the National Cancer Institute 2010, 102(5):298-306.
8. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. The New England Journal of Medicine 2005, 353(2):133-144.
9. Mack P.C., Holland W.S., Rebekah A.B., Sangha R., Solis L.J., Li Y., et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plu docetaxel-treated non-small cell lung cancer. Journal of Thoracic Oncology 2009, 4(12):1466-1472.
10. Grønberg B.H., Bremmes R.M., Fløtten Ø., Amundsen T., Brunsvif P.F., Hjelde H.H., et al. Phase III Study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line hemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2009, 27(19):3217-3224.
11. Lee D.H., Park K., Kim J.H., Lee J.S., Shin S.W., Kang J.H., et al. Randomized Phase III Trial of Gefitinib versus docetaxel in non-small-cell lung cancer patients who have previously received platinum-based chemotherapy. Clinical Cancer Research 2010, 16(4):1307-1314.